The EMA intends to update the Guidance concerning Additional Risk Minimisation Measures

The European Medicines Agency (“EMA”) has announced its intention to update the Agency’s existing guidance concerning additional risk minimisation measures (“aRMMs”). The revised version will provide extensive guidance on various tools for additional risk minimization....
By: Hogan Lovells

Array